ArticleJournal of cardiovascular pharmacology2026
SGLT2 Inhibitors Attenuate Neutrophil-Mediated Endothelial Injury in Coronary Artery Disease With Type 2 Diabetes Mellitus Through a GREM1-Associated Smad Signaling Axis.
Article in Journal of cardiovascular pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
abstractType 2 diabetes mellitus (T2DM) is a critical risk factor for coronary artery disease (CAD), with neutrophils contributing to CAD through acute inflammatory responses. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors offer cardiovascular benefits beyond glycemic control, but their mechanisms involving innate immunity and neutrophil function in T2DM-related CAD remain unclear. Neutrophils were isolated from healthy controls, patients with CAD and T2DM, and patients receiving SGLT2 inhibitor therapy. Bulk transcriptomic analysis, flow cytometry, ELISA, and western blotting were used to assess gene expression, signaling changes, and neutrophil activation. Co-cultures of neutrophils with luciferase-expressing human aortic endothelial cells (HAEC-Luc) assessed endothelial injury, and a diabetic rat model was used to assess in vivo cardiac injury. Results showed elevated peripheral neutrophil cell-free dsDNA, elastase 2, and GREM1 expression in patients with T2DM-CAD, reversed by SGLT-2 inhibitors. T2DM-CAD neutrophils induced significant endothelial injury, ameliorated by SGLT-2 inhibition, or GREM1 blockade. Mechanistically, SGLT-2 inhibitors suppressed GREM1, restored TGF-β/Smad signaling, and reduced neutrophil-mediated cytotoxicity. In vivo, SGLT-2 inhibitors alleviated cardiac damage in diabetic rat, with suppressed neutrophil activation and upregulated TGF-β signaling. Our findings suggest that increased GREM1 expression in neutrophils is associated with impaired Smad1/5/9-related signaling and enhanced endothelial injury in T2DM-CAD, and SGLT-2 inhibitors exert vascular protection through GREM1 downregulation and TGF-β/Smad pathway modulation, highlighting a novel immunoregulatory mechanism with translational potential for diabetic cardiovascular outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.